Literature DB >> 18646609

[High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors].

Ikuo Shimizu1, Naoaki Ichikawa, Mihoko Yotsumoto, Masahiko Sumi, Mayumi Ueno, Hikaru Kobayashi.   

Abstract

A 72-year-old male presented with oral bleeding resulting from acquired factor V (FV) inhibitor. We observed abnormalities in prothrombin time (PT) (8%) and activated partial thromboplastin time (APTT) (>200 seconds). FV activity was less than 3%, and a mixing test did not correlate with PT. FV inhibitor assay demonstrated 240 Bethesda units/ml. The patient also showed markedly decreased activity of Factors II (13%) and X (14%). Oral bleeding disappeared and coagulation abnormalities improved with prednisolone therapy. High titer FV inhibitor might affect coagulation assays even in a patient with normal factor activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646609

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  3 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors.

Authors:  Keiichi Nakata; Shuji Ueda; Hitomi Matsunaga; Fuka Mima; Hiroki Ueda; Aya Yoshioka; Sayoko Kaneko; Kazushi Maruo; Shayne Morris; Sayoko Yonemoto; Daisuke Hayashi; Naohiko Fujii; Hiroyuki Narahara; Yoshiaki Inui; Sumio Kawata
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

3.  Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.

Authors:  Shinsaku Imashuku; Takeshi Hasegawa; Kagekatsu Kubo; Masaki Nakato; Midori Shima
Journal:  Int Med Case Rep J       Date:  2011-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.